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Introduction: Sepsis refers to severe systemic inflammation leading to acute lung injury (ALI) and death. Introducing
novel therapies can reduce the mortality in ALI. Osteopontin (OPN), a secretory glycoprotein produced by immune
reactive cells, plays a deleterious role in various inflammatory diseases. However, its role in ALI caused by sepsis remains
unexplored. We hypothesize that treatment with an OPN-neutralizing antibody (anti-OPN Ab) protects mice against
ALI during sepsis.
Methods: Sepsis was induced in 8-week-old male C57BL/6 mice by cecal ligation and puncture (CLP). Anti-OPN Ab or
non-immunized IgG as control, at a dose of 50 μg/mouse, was intravenously injected at the time of CLP. After 20 hours,
the expression of OPN and proinflammatory cytokines in tissues and plasma was examined by real-time PCR, Western
blot, and ELISA. Plasma levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST) and lactate
dehydrogenase (LDH) and the lung myeloperoxidase (MPO) levels were determined by colorimetric assays. Lung
damage and neutrophil infiltrations were determined by histological H&E and Gr-1 staining, respectively. The effect of
recombinant mouse OPN (rmOPN) on human neutrophil-like cell (HL-60) migration was performed by Boyden chamber
assays and the involvement of intracellular signaling molecules in HL-60 cells was revealed by Western blot.
Results: After 20 hours of sepsis, mRNA and protein levels of OPN were significantly induced in lungs, spleen, and
plasma. Treatment with an anti-OPN Ab in septic mice significantly reduced the plasma levels of ALT, AST, and LDH,
and the proinflammatory cytokines IL-6, IL-1β and the chemokine MIP-2, compared with the vehicle group. Similarly, the
lung mRNA and protein expressions of proinflammatory cytokines and chemokine were greatly reduced in anti-OPN
Ab-treated animals. The lung histological architecture, MPO and neutrophil infiltration were significantly improved in
anti-OPN Ab-treated mice compared with the vehicle animals. Treatment of rmOPN in HL-60 cells significantly increased
their migration, in vitro. The neutrophils treated with rmOPN remarkably increased the levels of phospho focal adhesion
kinase (pFAK), phospho extracellular signal-regulated kinase (pERK) and phospho p38.
Conclusions: Our findings clearly demonstrate the beneficial outcomes of anti-OPN Ab treatment in protecting against
ALI, implicating a novel therapeutic strategy in sepsis.* Correspondence: pwang@nshs.edu
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Sepsis is a severe systemic inflammation that occurs
due to an abnormal host response against invading
pathogens. Septic patients suffer from a ‘cytokine storm’ as
a result of an exaggerated production of proinflammatory
cytokines, chemokines and other inflammatory mediators
[1]. Severe sepsis, complicated by acute organ dysfunction,
is recorded in 10% of all intensive care unit (ICU) admis-
sions and represents the most common cause of death
among hospitalized patients in the USA [2,3]. Acute lung
injury (ALI) or its more severe condition, acute respiratory
distress syndrome (ARDS) is the primary complication in
sepsis during the sequential development of multiple
organ dysfunction (MOF) [4]. Despite tremendous clinical
and scientific effort in this field, ALI/ARDS in sepsis
remain as considerable challenges to critical care medicine,
causing approximately 74,500 deaths per year [5]. Hence,
the development of novel therapeutic strategies for ALI/
ARDS is invaluable for critical care patients.
In sepsis, activated neutrophils transmigrate and infiltrate
into the lungs where they release a large number of
proteolytic enzymes, such as myeloperoxidase (MPO),
and reactive oxygen species (ROS) including hydrogen
peroxide and superoxide for elimination of invaded
pathogens [6,7]. However, overwhelming migration of
activated neutrophils into the lungs can lead to a
deleterious function by causing endothelial cell damage
and unrestrained inflammation [8,9]. In ARDS patients,
the intensity of neutrophil infiltrations correlates with the
severity of lung injury caused by neutrophil-derived
proteolytic enzymes and proinflammatory mediators
in the bronchoalveolar lavage [10]. Thus, it implies
that the regulation of neutrophil infiltration into the
lungs could be an effective therapeutic approach in
septic patients with ALI/ARDS.
Osteopontin (OPN) also known as bone sialoprotein I
(BSP-I), early T lymphocyte activation (ETA-1), or secreted
phosphoprotein 1 (SPP-1), is shown to be multifunctional
and implicated in the pathogenesis of a variety of diseases
[11-17]. In the immune system, OPN is synthesized by a
variety of immune cells including activated T cells, natural
killer (NK) cells, dendritic cells (DC), and macrophages
[18,19]. Through interactions with several integrins or
CD44, OPN mediates diverse cellular functions such as
adhesion, migration, and survival of several different cell
types, including regulating and propagating inflammatory
responses of macrophages, T cells, and DC [11]. The
existence of variant forms of OPN as a secreted (sOPN)
and intracellular (iOPN) protein and its modification
through posttranslational events and proteolytic cleavage
explains its broad range of functions [20]. Nascent OPN
protein undergoes posttranslational modifications including
serine/threonine phosphorylation, sulfation, glycosylation
and transglutamination [11]. In addition, OPN is also asubstrate for thrombin and the matrix metalloproteinases,
(MMP)-3, -7, -2, -9 and -12 to generate its different cleaved
fragments [11,21]. In human, OPN contains three cleavage
sites for MMPs, that is Gly166-Leu167, Ala201-Tyr202, and
Asp210-Leu211 [11]. Agnihotri et al. showed that cleavage of
the full-length OPN by MMP-3 and -7 at Gly166-Leu167
generates 40- and 32-kiloDalton (kDa) N- and C-terminal
fragments, respectively. The resultant 32-kDa C-terminal
fragment is further cleaved by thrombin at Arg168-Ser169 to
form a 25-kDa fragment [22]. The thrombin-cleaved
N-terminal fragment containing a RGD and SVVYGLR
sequences is capable of binding to several integrins, such
as αvβ3, αvβ5, α9β1, α4β1 and others to promote biological
functions [11]. On the other hand, the C-terminal
fragments transduce intracellular signals by binding to
CD44 [23]. Compared with chronic inflammatory diseases,
fewer reports focus on acute inflammatory diseases or
infection on OPN function [24-27]. It is therefore crucial
to delineate the pathophysiological role of OPN in
sepsis-induced ALI, and also becomes necessary to know
whether or not neutralization of OPN can ameliorate this
acute inflammatory disease condition. Within the diverse
functions, OPN can act as a chemoattractant for T
cells, monocytes/macrophage and neutrophils [28,29].
Considering the deleterious function of exaggerated
infiltration of neutrophils in lungs to cause sepsis-induced
ALI, we hypothesize that the blockage of OPN by its neu-
tralizing antibody (Ab) may effectively reduce neutrophil
migration into the lungs by modulating intracellular
signaling molecules required for cell migration, ultimately
attenuating sepsis-induced ALI.
Materials and methods
Animal model of sepsis
Eight-week-old male C57BL/6 mice purchased from
Taconic Biosciences (Albany, NY, USA) were housed in
a temperature-controlled room on a 12 h light/dark
cycle and fed a standard laboratory diet. Sepsis was
induced in mice by cecal ligation and puncture (CLP).
Mice were anesthetized by isoflurane inhalation, and the
abdomen was shaved and wiped with 10% povidone
iodine (PI). A 1-cm abdominal incision was performed
to expose the cecum. The cecum was tightly ligated with
a 4-0 silk suture 0.5 to 0.75 cm away from the tip and
punctured twice between the tip and the ligation with a
22-gauge needle to eject a small amount of feces from
the perforation sites by gentle squeezing. The cecum was
returned to the abdominal cavity and the laparotomy site
was closed with a 6-0 silk suture in two layers. The sham
animals underwent the same procedure with the exception
of the cecum neither ligated nor punctured. Animals were
resuscitated with 1 ml of normal saline subcutaneously. At
20 h after operation, mice were anesthetized and blood,
spleen and lung samples were collected. Blood samples
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The plasma and tissue samples were frozen immediately in
liquid nitrogen and stored at -80°C until analysis. A
section of lung tissue was preserved in formalin for
histopathological analysis. All experiments were performed
in accordance with the guidelines for the use of experimen-
tal animals by the National Institutes of Health (Bethesda,
MD, USA) and were approved by the Institutional Animal
Care and Use Committee (IACUC) at the Feinstein Institute
for Medical Research.
Administration of neutralizing OPN antibody
Mouse affinity purified polyclonal Ab, anti-OPN Ab
purchased from R&D Systems, Minneapolis, MN,
USA; Catalog No.: AF808, was used for neutralization
of OPN in vivo. According to the literature, the polyclonal
anti-OPN Ab is able to neutralize recombinant
OPN-mediated cell adhesion at a ND50 of 1 to 3 μg/ml,
in vitro. In addition, recent studies also demonstrated its
in vivo neutralizing function against endogenous OPN when
injected into experimental animals [30,31]. Immediately
after CLP, a small incision on the neck was performed to
expose the internal jugular vein. Phosphate-buffered saline
(PBS) or mouse anti-OPN Ab at a dose of 50 μg/mouse in
100 μl volumes was delivered by bolus injection through the
jugular vein to serve as vehicle and treatment groups,
respectively. In the same way, normal goat immunoglobulin
G (IgG) (R&D Systems; Catalog No.: AB-108-C) at a dose
of 50 μg/mouse in 100 μl volumes was injected in septic
animals to serve as the non-immunized IgG control for
anti-OPN Ab. The proximal and distal ends of the injected
jugular vein were tightly ligated with 5-0 silk suture to pre-
vent unwanted bleeding caused by injecting with anti-OPN
Ab using 29G× 1/2″ U-100 insulin syringe (Terumo
Medical Corporation, Elkton, MD, USA). Ligation of one of
the paired veins did not interrupt the blood flow from the
head back to the heart. The wound was closed with one
interrupted 6-0 silk suture.
Measurement of organ injury markers
Plasma levels of aspartate aminotransferase (AST),
alanine aminotransferase (ALT) and lactate dehydrogenase
(LDH) were measured using commercial assay kits (Pointe
Scientific, Lincoln Park, MI, USA) according to the manu-
facturer’s instructions.
Measurement of proinflammatory cytokines and
chemokine
Proinflammatory cytokines, interleukin 6 (IL-6) and IL-1β
in plasma and lung tissues were quantified by using the
mouse enzyme-linked immunosorbent assay (ELISA) kits
(BD Biosciences, Franklin Lakes, NJ, USA). Macrophage
inflammatory protein (MIP)-2 in plasma and lung tissueswas measured by using the mouse ELISA kit (R&D
Systems).
Histological examination and immunostaining
The lung tissue was fixed in 10% formalin and then
embedded in paraffin. Later, the tissue blocks were cut
into 5-μm sections, placed onto glass slides and stained
with hematoxylin and eosin (H&E), dehydrated, and
mounted. Morphologic examinations in these tissues
were evaluated by light microscopy in a blinded fashion.
To examine the extent of lung injury, we considered
its five pathological features, such as (i) presence of
exudates, (ii) hyperemia/congestion, (iii) intra-alveolar
hemorrhage/debris, (iv) cellular infiltration, and (v)
cellular hyperplasia. The severity of each of these patho-
logical features was evaluated by a score indicating 0 as
absent/none, 1 as mild, 2 as to show moderate, and finally
3 for severe injury. Compilations of these values obtained
from individual pathological features represent the lung
injury score [7,32].
Gr-1 is a 21- to 25-kDa myeloid differentiation protein
and also known as Ly-6G/Ly-6C. This myeloid differenti-
ation antigen is a glycosylphosphatidylinositol (GPI)-linked
protein expressed on granulocytes and macrophages. In the
bone marrow, expression levels of Gr-1 directly correlate
with granulocyte differentiation and maturation [33]. To
examine neutrophil infiltration in lungs we performed
immunohistochemistry using anti-Gr-1 Ab (BioLegend, San
Diego, CA, USA; Catalog No.: 108413) as described previ-
ously [7]. In brief, 10% formalin-fixed, paraffin-embedded
lung tissues were dewaxed in xylene and rehydrated in a
graded series of ethanol. The slides were heated in 0.92%
citric acid buffer (Vector Laboratories, Burlingame, CA) at
95°C for 30 min. After cooling to room temperature, the
slides were incubated with 2% H2O2 in 60% methanol and
blocked in 2% normal rabbit serum/Tris-buffered saline.
Anti-Gr-1 antibody (BioLegend) was then applied and
incubated overnight. Vectastain ABC reagent and
DAB kit (Vector Laboratories) were used to detect the
immunohistochemical reaction. Slides were counterstained
with 4′, 6-diamidino-2-phenylindole and examined under
a phase contrast light microscope (Eclipse Ti-S; Nikon,
Melville, NY, USA). Gr-1-positive staining cells were
counted in 10 visual fields/section at × 200 magnification,
and averaged number was calculated.
Myeloperoxidase activity assay
Lung tissues were homogenized in potassium phosphate
buffer containing 0.5% hexadecyl trimethyl ammonium
bromide by sonication. After the samples were centrifuged,
the supernatant was diluted in reaction solution containing
o-dianisidine hydrochloride and H2O2 in PBS. The rate of
change in optical density (OD) for 1 min was measured at
460 nm to calculate MPO activity.
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Total RNA was extracted from lung tissues by using
TRIzol (Invitrogen, Carlsbad, CA, USA) and was
reverse-transcribed into cDNA using reverse transcriptase
(Applied Biosystems, Foster City, CA, USA). A polymerase
chain reaction (PCR) was carried out in 25 μl of final
volume containing 0.1 μM of each forward and reverse
primer, cDNA and 12.5 μl SYBR Green PCR Master Mix
(Life Technologies, Grand Island, NY, USA). Amplification
was conducted using an Applied Biosystems 7300 real-
time PCR machine under the thermal profile of 50°C for
2 min, 95°C for 10 min followed by 45 cycles of 95°C for
15 seconds and 60°C for 1 min. For relative quantization,
2-ddCt method normalized to mouse β-actin mRNA was
used. Relative expression of mRNA was expressed as the
fold change in comparison with the sham tissues. The
primers used for this study are: OPN (NM_001204201)
Forward: TCTGATGAGACCGTCACTGC, Reverse: AGG
TCCTCATCTGTGGCATC; IL-6 (NM_031168) Forward:
CCGGAGAGGAGACTTCAC AG, Reverse: GGAAATTG
GGGTAGGAAGGA; MIP-2 (NM_009140) Forward:
CCCTGG TTCAGAAAATCATCCA, R: GCTCCTCCTT
TCCAGGTCAGT; IL-1β (NM_008361) F: CAGGATGAG
GACATGAGCACC, R: CTCTGCAGACTCAAACTC
CAC; β-Actin (NM_00 7393): F-CGTGAAAAGATGAC
CCAGATCA, R-TGGTACGACCAGAGGCATACAG.
Migration assay
Human promyelocytic HL-60 cells were obtained from the
American Type Culture Collection (Manassas, VA, USA)
and cultured in RPMI medium (Invitrogen) containing 10%
fetal bovine serum (FBS), glutamine, penicillin and
streptomycin. HL-60 cells were differentiated into
neutrophil-like cells (dHL-60) by adding dimethyl
sulfoxide (DMSO) at (12.7 μl/ml per million cells) for
5 days. The differentiated HL-60 cells (1.5 × 106 cell/ml)
were pretreated with PBS (DMSO), or extracellular signal-
regulated protein kinase (ERK) inhibitor (PD98059, 50 μM),
or p38 inhibitor (SB203580, 50 μM) for 1 h. The migration
assays were performed in a modified 24-well (3.0-μm pore)
Boyden chamber using falcon cell culture inserts (BD
Biosciences). Recombinant mouse osteopontin (rmOPN)
purchased from R&D Systems (Catalog No.: 441-OP) was
used as a chemoattractant for dHL-60 cell migration.
rmOPN was prepared by cloning the cDNA encoding
Leu17 to Asn294 (Glu99Gly) of OPN transcript without its
signal peptide sequence (Accession No.: Q547B5) into a
C-terminal 6-His tag expression vector. The expression
and purification of rmOPN protein were carried out in a
mouse myeloma cell line, NS0. The cells were plated in
the upper well, and medium containing PBS or rmOPN at
a dose of 10 μg/ml was placed in the lower well as a
chemotactic stimulus. After 2 h, the upper surface of the
filter was washed and swabbed with cotton to removenon-migratory cells. Migrated cells were fixed with 10%
formalin. PI was used for staining the migrated cells and
observed under a fluorescence microscope. Cell number
was counted in five random microscopic fields per well. In
order to examine the role of rmOPN for primary neu-
trophil migration, mice bone marrow neutrophils were
isolated as described previously [6] and the migration
assay was performed by following the above method used
for HL-60 cell migration.
Intratracheal administration of rmOPN and assessment of
neutrophil migration in lungs
Male (25 to 30 g) age-matched C57BL/6 J (Taconic
Biosciences) mice were anesthetized with isoflurane
and the trachea was surgically exposed, lifted, and
then instilled with either 40 μl of sterile PBS or
rmOPN at a dose of 2.5 μg/mouse using 29G × 1/2″
U-100 Insulin Syringe (Terumo Medical Corporation).
The wound was closed with 6-0 silk suture. After 20 h of
rmOPN administration, lung tissues were removed and
cut into 300 mm pieces, and digested in RPMI 1640
containing 10% FBS, 100 U penicillin/streptomycin,
20 mM L-glutamine, 100 U/ml collagenase type 1
(Worthington Biochemical Corp., Lakewood, NJ,
USA) and 20 U/ml DNase 1 (Roche Diagnostics,
Mannheim, Germany) for 60 min in a 37°C water
bath with shaking. Any remaining intact tissue was
disrupted by passage through a 21G needle. The digested
tissue contents were then passed through a 70 μm Nylon
mesh (BD Biosciences), centrifuged and washed. A total of
1 × 106 cells were stained with APC-labeled anti-mouse
Gr-1 Ab (BioLegend) and subjected for flow cytometry
analysis.
Western blot analysis
Spleen and lung tissues and dHL-60 cells (1.5 × 106 cells)
treated with 2 μg/ml of rmOPN for 90 min were
homogenized in lysis buffer (10 mM Tris-HCl, pH 7.5,
120 mM NaCl, 1% NP-40, 1% sodium deoxycholate and
0.1% sodium dodecyl sulfate) containing a protease
inhibitor cocktail (Roche Diagnostics). Protein concen-
tration was determined by Bio-Rad Laboratories
(Hercules, CA, USA) protein assay reagent. Total lysates
and plasma were fractionated on Bis-Tris gels (4% to
12%) and transferred to nitrocellulose membrane. The
membranes were then blocked with 5% nonfat dry milk
in Tris-buffered saline with Tween-20 (TBST) and incu-
bated overnight at 4°C with the primary antibodies as
obtained from respective vendors: anti-OPN Ab (Santa
Cruz Biotechnology, Santa Cruz, CA, USA), anti-
phospho-focal adhesion kinase (FAK) (Tyr397) Ab,
anti-FAK Ab, anti-phospho-p44/42 mitogen-activated
protein (MAP) kinase (pERK) (Thr202/Tyr204) Ab,
anti-p44/42 MAP kinase (ERK) Ab, anti-phospho-p38
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kinase Ab (Cell Signaling Technology, Beverly, MA,
USA), and anti-β-actin Ab from Sigma-Aldrich (St Louis,
MO, USA).
Statistical analysis
Data are expressed as mean ± standard error of the mean
(SEM) and analyzed using Sigma Plot11 graphing and
statistical analysis software (Systat Software Inc., San
Jose, CA, USA). Multiple groups were compared by
one-way analysis of variance (ANOVA) using the































































Figure 1 Expression of OPN in lungs, spleen and plasma after sepsis
after CLP or sham operation. Lung expression of OPN at its (A) RNA and (B
blot, respectively. OPN expression in the spleen tissues was determined at
normalized to β-actin expression and the value of sham group was design
from sham and CLP animals was determined by Western blot. Each blot w
OPN and β-actin are shown. Data are expressed as means ± SEM (n = 5 mic
CLP, cecal ligation and puncture; OPN, osteopontin; PCR, polymerase chainused for two-group analysis. Differences in values were
considered significant if P <0.05.
Results
OPN expression is upregulated in the lungs, spleen and
plasma after sepsis
To assess the alteration of OPN expression after 20 h of
CLP, the lung and spleen tissues of sham and CLP mice
were examined by Western blot and quantitative PCR
analysis. In the lung tissues, the RNA expression of OPN
in the CLP group was significantly upregulated by 1.9-fold




















































in mice. Lungs, spleen and blood samples were harvested at 20 h
) protein levels was measured by using real-time PCR and Western
its (C) RNA and (D) protein levels. OPN expression in each sample was
ated as one for comparison. (E) OPN expression in 3.0 μL of plasma
as quantified by densitometry analysis. Representative blots against
e/group) and compared by Student’s t test (*P <0.05 vs. shams).
reaction; SEM, standard error of the mean.
Hirano et al. Critical Care  (2015) 19:53 Page 6 of 15the protein expression by Western blot, we detected three
bands with the molecular weights of about 65-, 55-, and
25-kDa, respectively, which represented different
cleaved fragments of OPN (Figure 1B). Summing up
the densitometry values of all the OPN fragments in the
lung tissues of each group showed significant upregulation
of its total contents in CLP animals as compared to the
sham animals (Figure 1B). Similarly, in spleen, the RNA
and total protein expression of OPN in the CLP
group were significantly upregulated by 3.2- and 2.0-fold
in CLP animals than that of sham group, respectively
(Figures 1C,D). In contrast, instead of multiple bands
the plasma samples showed 25-kDa OPN form alone.
The reason for not getting the 65- and 55-kDa OPN





















































Figure 2 Effect of anti-OPN Ab treatment on plasma levels of organ i
CLP animals. Sepsis was induced in mice by CLP and anti-OPN Ab or non
was injected through the jugular vein. In the vehicle group, 100 μl of PBS w
drawn by cardiac puncture at 20 h of sham-operated, vehicle and anti-OPN
the blood samples collected at 20 h after CLP were measured for (D) IL-6,
(n = 5 mice/group) and compared by one-way ANOVA and SNK method (*
aminotransferase; ANOVA, analysis of variance; AST, aspartate aminotran
immunosorbent assay; IgG, immunoglobulin G; IL, interleukin; LDH, lactate de
osteopontin; PBS, phosphate-buffered saline; SEM, standard error of the meanof albumin (molecular weight: 66 kDa) in the plasma,
which hampered the detection of other posttranslational
modified forms of OPN in plasma by Western blot. As
shown in Figure 1E, the 25-kDa OPN fragment was
elevated in the plasma from the CLP mice as compared to
the sham group.
OPN neutralization decreases organ injury and systemic
inflammatory responses after sepsis
Clinical markers such as AST, ALT, and LDH in blood
were measured at 20 h after CLP in mice to assess the
extent and severity of organ injury. Compared with the
sham group, the levels of AST, ALT and LDH were signifi-
cantly elevated in the vehicle group, as well as in the non-


























































njury markers and proinflammatory cytokines and chemokine in
-immunized IgG control at a dose of 50 μg/mice in 100 μl volumes
as injected in CLP mice via the jugular vein. Blood samples were
Ab-treated mice for measuring (A) ALT, (B) AST and (C) LDH. Similarly,
(E) IL-1β and (F) MIP-2 by ELISA. Data are expressed as means ± SEM
P <0.05 vs. shams; #P <0.05 vs. vehicle). Ab, antibody; ALT, alanine
sferase; CLP, cecal ligation and puncture; ELISA, enzyme-linked
hydrogenase; MIP-2, macrophage inflammatory protein 2; OPN,
; SNK, Student-Newman-Keuls.
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reduced the levels of these injury markers by 38%, 42%,
and 45%, respectively, as compared with the vehicle group
(Figures 2A-C). We have also examined the effect of anti-
OPN Ab treatment on systemic levels of proinflammatory
cytokines and chemokine. The plasma levels of IL-6, IL-1β
and MIP-2 were significantly increased in the vehicle
group as compared with the sham group, whereas
treatment with anti-OPN Ab significantly decreased
the plasma levels of IL-6, IL-1β and MIP-2 by 88%,
73% and 60%, respectively, as compared with the vehicle
animals (Figure 2D-F). Conversely, the animals injected
with non-immunized IgG control did not show any
notable reduction in the levels of plasma cytokines and
































































Figure 3 Effect of anti-OPN Ab on the expression of proinflammatory
subjected to CLP and 100 μl of anti-OPN Ab (50 μg/mouse) or PBS as vehic
after 20 h from sham-operated, vehicle, and anti-OPN Ab-treated mice. The
by real-time PCR. Gene expression was normalized to β-actin. The sham ex
of total protein extracted from the lung tissues were examined for (D) IL-6, (E
as per mg of proteins. Data are represented as means ± SEM (n = 5 mice/grou
sham; #P <0.05 vs. vehicle). Ab, antibody; ANOVA, analysis of variance; CLP, ce
interleukin; MIP-2, macrophage inflammatory protein 2; OPN, osteopontin; PB
standard error of the mean; SNK, Student-Newman-Keuls.could not find any noticeable difference of plasma injury
as well as inflammation markers between vehicle and
non-immunized IgG control groups, it is therefore logical
that the parameters in tissues after treatment with IgG
control might not differ from the vehicle group.
OPN neutralization inhibits cytokines and chemokine
expression in the lungs after sepsis
Apart from the blood, we have also investigated the expres-
sions of cytokines and chemokine in the lung tissues at
their RNA and protein levels by real-time PCR and ELISA,
respectively. Both the RNA and protein contents of IL-6 in
the lung tissues were significantly increased in the vehicle
group as compared with the sham group (Figure 3A,D).









































































cytokines and chemokine in the lungs after CLP. Mice were
le was injected through the jugular vein. Lung tissues were collected
tissue expression of (A) IL-6, (B) IL-1β and (C) MIP-2 was determined
pression level was designated as one for comparison. Similarly, 50 μg
) IL-1β and (F) MIP-2 analysis by ELISA. Finally, the results are expressed
p) and compared by one-way ANOVA and SNK method (*P <0.05 vs.
cal ligation and puncture; ELISA, enzyme-linked immunosorbent assay; IL,
S, phosphate-buffered saline; PCR, polymerase chain reaction; SEM,
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60%, respectively, as compared with the vehicle mice
(Figure 3A,D). The expression levels of IL-1β in both
RNA and proteins in the lung tissues were markedly
upregulated in the vehicle group as compared with the
sham group. Although not significant there was a clear
trend in downregulating its RNA and protein levels by
34% and 28%, respectively, in anti-OPN Ab-treated
animals than the vehicle group (Figure 3B,E). The RNA
expression of MIP-2 in the lung tissues was significantly
increased in the vehicle group as compared with the
sham group and it was dramatically decreased in
anti-OPN-Ab-treated animals by 79% than the vehicle
mice (Figure 3C). Although not significant, MIP-2 protein
expression in the lungs was found to be notably decreased
by 21% after anti-OPN-Ab treatment in septic mice as
compared with the vehicle-treated animals (Figure 3F).
OPN neutralization protects against sepsis-induced ALI
in mice
To clarify the effect of neutralizing OPN on the ALI
caused by CLP, lung tissue histology was performed and
the severity of injury was graded with an established
scoring system as described in the Materials and
Methods. Representative histological architectures of the
sham, vehicle, and anti-OPN-Ab-treated mice are shownShamA
B
OPN Ab
Figure 4 Evaluation of lung histology in mice after CLP. Lung tissues w
Ab-treated mice and stained with H&E. Slides were observed under light micro
(A) Representative images for sham, vehicle, and anti-OPN Ab treatment group
were quantified as described in the Materials and Methods. Data are expressed
and SNK method (*P <0.05 vs. shams; #P <0.05 vs. vehicles). Ab, antibody; ANOV
and eosin; OPN, osteopontin; SEM, standard error of the mean; SNK, Student-Nin Figure 4A. The lung tissues in the vehicle group pre-
sented substantial morphological changes including
edema, hemorrhage, alveolar collapse, and inflammatory
cell infiltrations as compared with the sham group. In
contrast, the treatment with anti-OPN-Ab dramatically
reduced the microscopic deterioration in comparison
with the vehicle group. As quantified in Figure 4B, the
lung tissue in the vehicle group exhibited a significant
increase in the histological injury score as compared with
the sham group, whereas the treatment with anti-OPN Ab
significantly improved the lung histological injury score as
compared with vehicle group.
OPN neutralization reduces neutrophil infiltration and
MPO activity in the lungs after sepsis
ALI is directly correlated with the number of infiltrated
neutrophils in the lungs. We therefore performed Gr-1
staining, a surface marker of activated neutrophils in the
lungs, after 20 h of CLP and the representative pictures
of immunohistochemistry in the sham, vehicle, and
anti-OPN-Ab-treated mice are shown in Figure 5A.
The number of Gr-1-positive cells in the lung tissues
was significantly increased in the vehicle group as
compared with the sham group. In contrast, there
were significantly lower numbers of Gr-1-positive cells



















Sham Vehicle OPN Ab
CLP
ere harvested after 20 h from sham-operated, vehicle and anti-OPN
scopy at × 200 original magnifications (inset: ×400 original magnification).
s are shown. (B) Histological injury scores of the lungs in different groups
as means ± SEM (n = 5 mice/group) and compared by one-way ANOVA

















































Sham Vehicle OPN Ab
CLP
B
Figure 5 Assessment of neutrophil infiltration into the lungs after CLP. Lung tissues were collected at 20 h after sham-operation, vehicle
and anti-OPN Ab treatment in mice. (A) Representative images of the lung tissue sections with immunostaining against Gr-1 at × 200 original
magnification are shown. Arrows demarcate examples of areas of staining Gr-1-positive cells. (B) A graphical representation of Gr-1-positive
cells averaged over 10 microscopic fields per animal lung tissues. (C) Myeloperoxidase (MPO) activities in lung tissues were determined
spectrophotometrically. Data are expressed as means ± SEM (n = 5 mice/group) and compared by one-way ANOVA and SNK method (*P <0.05
vs. shams; #P <0.05 vs. vehicles). Ab, antibody; ANOVA, analysis of variance; CLP, cecal ligation and puncture; OPN, osteopontin; SEM, standard
error of the mean; SNK, Student-Newman-Keuls.
Hirano et al. Critical Care  (2015) 19:53 Page 9 of 15mice (Figures 5A,B). Furthermore, the tissue damage in
ALI is also linked with the MPO activity within the lung.
The MPO activity in the lung tissue harvested at 20 h after
CLP was significantly increased in the vehicle group as
compared with the sham animals, whereas injecting
anti-OPN Ab significantly inhibited its activity by 37%
in comparison with the vehicle group (Figure 5C).
Administration of rmOPN intratracheally induces
neutrophil migration in lungs
To examine the direct role of OPN for neutrophil migra-
tion in lungs, we injected rmOPN in lungs intratracheallyand assessed neutrophil infiltration in lung tissues. As
shown in Figure 6A and B, under normal condition the
percentage of lung neutrophil content was negligible.
However, administration of rmOPN into the lungs
significantly increased the percentage of lung neutro-
phils as revealed by the Gr-1-positive cells. In order
to validate our in vivo finding, we have carried out an
in vitro experiment that also revealed rmOPN-mediated
dramatic increase of primary neutrophil migration
(Figure 6C and D). These data clearly demonstrate














































Figure 6 rmOPN-mediated neutrophil migration in vivo and in vitro. C57BL/6 mice were injected with rmOPN at a dose of 2.5 μg/mice,
intratracheally. After 20 h, cells from the lung tissues were isolated and stained with APC-anti-Gr-1 Ab and then subjected to flow cytometry.
(A) Representative dot blots indicating the percentages of Gr-1-positive cells are shown. (B) The mean percentages of Gr-1-positive cells
obtained from PBS- and rmOPN-injected mice are shown. Data are expressed as means ± SEM (n = 4 mice/group) and compared by Student’s
t test (*P <0.05 vs. PBS). (C) A total of 5 × 105 primary neutrophil cells isolated from mouse bone marrow were placed into the insert of a Boyden
chamber. The bottom compartment contained the RPMI medium with PBS or rmOPN at a dose of 10 μg/ml as a chemotactic stimulus. After 2 h, the
migrated primary neutrophil cells were counted. A representative image of the migrated primary neutrophil cells labeled with PI (red fluorescence) on
the bottom of the transwell membrane is shown. Cells were observed at × 200 original magnification. (B) Migrated primary neutrophils were counted
in five random microscopic fields per well and averaged in each group. Data are expressed as means ± SEM (n = 4/group) and compared by Student’s
t test (*P <0.05 vs. PBS). Ab, antibody; OPN, osteopontin; PBS, phosphate-buffered saline; PI, propidium iodide; rmOPN, recombinant mouse OPN; SEM,
standard error of the mean.
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neutrophils
MAP kinases play pivotal roles in efficient neutrophil
migration [34,35]. Integrins serve as the pivotal receptors
for OPN-mediated signaling [11]. To reveal the mechanism
of OPN-mediated neutrophil migration we used a human
differentiated neutrophil cell line, dHL-60 cells. At first, to
determine the integrin-mediated signaling after treat-
ment with rmOPN in dHL-60 cells, phosporylation of
the integrin-associated downstream molecule, FAK was
examined. Neutrophils treated with rmOPN dramatically
upregulated pFAK levels over that of controls, indicating it
to be an essential molecule for OPN-mediated downstream
signaling (Figure 7A). Furthermore, to assess the involve-
ment of OPN in MAP kinase pathway, the phospholyration
levels of ERK and p38 in the dHL-60 cells treated with
rmOPN were determined by Western blot. In the dHL-60
cells pretreated by rmOPN, the phospholyration of
these kinases were remarkably higher as compared with
the PBS-treated dHL-60 cells, indicating OPN-mediated
downstream signaling could be generated through FAK
and MAP kinases (Figure 7B,C).rmOPN promotes neutrophil migration via ERK and p38
MAP kinase activation in vitro
To examine the effect of rmOPN on neutrophil migration,
dHL-60 cells were subjected to a Boyden chamber assay.
In the PBS-pretreated dHL-60 cells, comparably higher
numbers of migrated cells were detected at the bottom of
the micropore membrane when rmOPN was used as a
chemoattractant in the lower chamber (Figures 8A,B).
However, pretreatment of the cells with ERK or p38
inhibitors significantly downregulated the dHL-60 cell
migration towards rmOPN by 54% and 60%, respect-
ively as compared with the PBS-treated dHL-60 cells
(Figures 8A,B). Collectively, these data clearly revealed that
the rmOPN-mediated dHL-60 cell migration occurred
through the induction of the MAP kinase pathway.
Discussion
Osteopontin plays diverse cellular functions in innate
immune system starting from promoting T helper cell
type 1 (Th1) skewing and extended through the dif-
ferentiation and proliferation of immune reactive cells


















































Figure 7 rmOPN-mediated activation of FAK and MAP kinase
signaling molecules in dHL-60 cells. Differentiated HL-60 cells were
incubated with PBS or rmOPN at a dose of 2 μg/mL for 90 min. (A)
The status of phosphorylated FAK (pFAK) and β-actin, (B) pERK and
total ERK and (C) pp38 and total p38 in each group was determined
by Western blot. Blots were scanned and quantified with densitometry.
Representative blots against these proteins are shown. Data are
expressed as means ± SEM obtained from two independent
experiments (n = 5/group) and compared by Students t test (*P <0.05
vs. PBS). ERK, extracellular signal-regulated protein kinase; FAK, focal
adhesion kinase; MAP, mitogen-activated protein; OPN, osteopontin;
PBS, phosphate-buffered saline; rmOPN, recombinant mouse OPN;
SEM, standard error of the mean.
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tissue damage [11]. Considering its above features, we
aim to reveal its expression, function and therapeutic
implication in murine experimental sepsis. Our current
study demonstrates an increased expression of OPN inlungs and spleen tissues, as well as in the plasma of septic
animals. A strategy utilizing the neutralizing Ab against
OPN dramatically reduced systemic inflammatory
responses, organ injuries, and neutrophil infiltration into
the lungs, leading to the improvement of the integrity of
lung architecture and downregulation of MPO activity
after sepsis. It is reasonable to think that the overall
improvement of sepsis by neutralizing OPN could be due
to the inhibition of systemic inflammatory and injury
markers in general. Correspondingly, the decreased levels
of MIP-2, a potent chemoattractant for neutrophils in
plasma as well as in lungs after sepsis in animals treated
with anti-OPN Ab might also indirectly regulate excess
neutrophil migration at the infectious foci as well as
in remote organs. Interestingly, our in vivo finding
demonstrating excessive neutrophil migration in lungs
as a result of intratracheal rmOPN injection provided
direct involvement of OPN-mediated induction of ALI
(Figure 6A,B), which might in turn be reversed by
administrating neutralizing Ab against OPN to attenuate
lung neutrophil migration in sepsis-induced ALI. Moreover,
our in vitro approaches clearly confirmed OPN as a potent
chemoattractant for neutrophil migration directly by upreg-
ulating MAP kinase pathway molecules, p38 and ERK with
the fact that utilizing their inhibitors greatly diminished the
OPN-mediated neutrophil migration. OPN can recognize
several integrins, such as αvβ3, αvβ5, αvβ1, α8β1 and others
as its receptors for signal transduction [38]. Since these
integrins are known to activate FAK [39-41], it is therefore
meaningful to examine the effect of OPN for FAK
activation in neutrophil cells.
OPN is strikingly upregulated at the sites of inflammation
and during tissue remodeling [42,43]. As a proinflammatory
cytokine, increased levels of OPN have been demonstrated
in a variety of chronic inflammatory diseases including
Crohn’s disease, cancer, atherosclerosis, aortic abdominal
aneurysms, and autoimmune diseases [11-17]. In contrast,
a few studies were performed to focus on its expression
during acute inflammatory disease conditions. Studies using
the human subjects, Vaschetto et al. have recently reported
increased concentration of plasma OPN in sepsis patients
[27]. In our study, we have also noticed significant
upregulation of OPN in plasma as well as in lung and
spleen tissues at 20 h after sepsis. Sepsis is characterized
by a biphasic immunological phenomenon where the early
acute hyperinflammatory phase is accompanied by the
immunosuppressive phase at the late stage of sepsis [1]. In
our current study, we have emphasized the early acute
phase of sepsis to demonstrate the effects of anti-OPN Ab
as a preventive approach. However, the setting up of an
anti-OPN Ab-based treatment strategy in sepsis consider-
ing its pathophysiological window period in mice would
reflect its clinical relevancy. Recently, Vaschetto et al.
measured the levels of OPN for fifteen days in patients
Figure 8 Effect of rmOPN on dHL-60 cell migration in vitro. Boyden chamber assay was performed as described in Materials and Methods.
(A) A representative image of migrated dHL-60 cells labeled with PI (red fluorescence) on the bottom of the transwell membrane. Cells were
observed at × 200 original magnification. (B) Migrated dHL-60 cells were counted in five random microscopic fields per well and averaged in
each group. Data are expressed as means ± SEM (n = 4/group) and compared by one-way ANOVA and SNK method (*P <0.05 vs. PBS; #P <0.05 vs.
rmOPN). ANOVA, analysis of variance; OPN, osteopontin; PBS, phosphate-buffered saline; PI, propidium iodide; rmOPN, recombinant mouse OPN;
SEM, standard error of the mean; SNK, Student-Newman-Keuls.
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creased levels of OPN started at four days before shock
development [44]. Thus, OPN can be considered as the
prognostic marker of shock and the therapeutic measures
targeting OPN should be implemented based on this
window period. However, a recent article strongly suggests
that the mouse models to study sepsis differ from what is
seen clinically in humans [45]. This is due to the fact that
rodents are highly resistant to most types of induced
inflammation compared with humans. Moreover, compared
with what is seen in sepsis syndrome in humans, micewithin a CLP model tend to have a shorter duration of the
disease, which is often terminated with a quite sudden
death and less organ failure [45]. As a result of the
discrepancies between human and animal models of
sepsis, the actual window period of the disease can
vary and the treatment strategy may not be truly
transferable to the clinical practice. Considering the
aberrant expression of OPN in lungs, we next attempted
to delineate whether or not it plays a deleterious role in
lungs during sepsis. OPN’s role as a chemoattractant to
promote the migration of immune cells to the site of
Hirano et al. Critical Care  (2015) 19:53 Page 13 of 15inflammation has been demonstrated in earlier studies
[11,23]. Nonetheless, the majority of the reports were
mainly based on the role of OPN on macrophage migration.
Correspondingly, Bruemmer et al. also have shown that
acute macrophage infiltration was dramatically diminished
in OPN-null mice compared to wild-type mice in a
thioglycollate-induced peritonitis model [46]. In our current
study, we for the first time revealed the role of OPN for
neutrophil migration into the lungs during polymicrobial
sepsis in mice. Consistent with our findings, OPN was
shown to be upregulated and associated with neutrophil
and macrophage infiltration in glioblastoma, the most
invasive type of brain tumors/glioma [47]. In our
study, administration of the neutralizing Ab against
OPN in mice during sepsis greatly ameliorated the
contents of infiltrating neutrophils in the lungs, thereby
protecting mice from developing ALI induced by sepsis.
Similar to our approach, a recent study has also shown that
the antibody-mediated neutralization of OPN significantly
reduced the obesity-induced inflammation and insulin
resistance in mice [48]. Beside this report, Fortis et al. have
recently demonstrated reduced levels of plasma cytokines
and chemokines in OPN knockout mice in a murine model
of sepsis [49], which indirectly validated our approach for
attenuating sepsis-associated ALI in mice by the treatment
of anti-OPN Ab. Although the above study revealed a
deleterious role of OPN in sepsis, the mechanism remained
unexplored. In our current study, we therefore not only
demonstrated the beneficial outcomes of OPN-neutralizing
Ab in sepsis-induced ALI, but also elucidated intracellular
signaling events involving the activation of ERK and
P38 MAP kinases to govern OPN-induced neutrophil
migration. Hence, our approach for utilizing anti-OPN Ab
as a potential therapeutic tool for treating ALI caused by
excessive neutrophil infiltration is permissible. It has
previously been demonstrated that the MAP kinases
play a pivotal role in cell migration [34]. The involvements
of ERK and P38 MAP kinases for neutrophil migration
have been well characterized in recent studies [50,51]. In
contrast, the stress-activated protein kinases (SAPK)/Jun
amino-terminal kinases (JNK) are best known for their
pivotal roles in cellular growth, differentiation, survival, and
apoptosis [52] and are less focused on neutrophil migration.
We therefore emphasized evaluating the phosphorylation
status of ERK and P38 for OPN-mediated neutrophil
migration. Beside this, FAK and its signaling pathways are
also involved in cell migration [53]. In an in vitro system
we have noticed considerable upregulation of ERK, p38 and
FAK in human neutrophil cell line treated with rmOPN.
Besides, we also confirmed the involvement of ERK and
p38 for OPN-mediated neutrophil migration by using
their inhibitors, which showed dramatic decrease in
OPN-mediated neutrophil migration. Moreover, our study
showing remarkable upregulation of pFAK by rmOPNtreatment not only indicated the pFAK’s role in cellular
migration, but also clarified its upstream signaling event
that could be mediated through the interaction of its
N-terminal RGD motif and αvβ3-integrin. Recently, a
bidirectional regulatory role of MAP kinase for neutrophil
migration has been demonstrated where the activation
of p38 molecule enhanced the chemokine-mediated
neutrophil migration, while the activation of ERK
pathway inhibited their migration [50]. In this study,
they have utilized a potent chemokine, fMLP, to show the
bidirectional regulatory roles of MAP kinases that medi-
ated through the G-protein coupled receptor kinase-2
(GRK-2). On the other hand, we have utilized a different
chemoattractive molecule, OPN, which could promote the
downstream signaling for neutrophil migration via recog-
nizing its integrin receptor without involving the GRKs.
Apart from the direct neutrophil infiltration in lungs,
ALI can also be aggravated by elevated systemic/local
proinflammatory cytokines and chemokines, which may
indirectly promote immune cell infiltration in lungs.
Utilizing the OPN knockout mice Van der Windt et al.
demonstrated reduced plasma levels of proinflammatory
cytokines and chemokines in Streptococcus pneumonia-
infected animals [24]. Similarly, in our study utilizing the
OPN blocking strategy by its neutralizing Ab significantly
attenuated the IL-6, IL-1β and MIP-2 levels not only in
the blood but also in lungs, which we suggest that the
anti-OPN Ab-mediated mitigation of ALI could also be
due to the downregulation of proinflammatory cytokines
and chemokines. Likewise, neutralizing OPN may generate
potential beneficial outcomes in an array of inflammatory
diseases.
Conclusions
In conclusion, we have clearly demonstrated the protective
role of anti-OPN Ab against ALI after sepsis in mice by
inhibiting neutrophil migration in lungs. In addition, we
have also revealed the intracellular signaling cascade for
neutrophil migration activated by osteopontin through the
upregulation of MAP kinase pathway, which may further
contribute to novel drug development for inhibiting
neutrophil migration in sepsis-induced ALI. Further stud-
ies to delineate effective dose and timing of administration
will be helpful for future clinical trials with ALI patients,
which not only save their lives, but also relieve economic
burden.
Key messages
 OPN expression is upregulated in plasma and multiple
organs (lungs and spleen) after sepsis in mice.
 OPN neutralization decreases systemic levels of
proinflammatory cytokines as well as organ injury
markers after sepsis in mice.
Hirano et al. Critical Care  (2015) 19:53 Page 14 of 15 OPN neutralization improves the integrity of lung
architecture and attenuates neutrophil infiltration
as well as MPO activity in the lungs after sepsis
in mice, resulting in the protection against
sepsis-induced ALI.
 OPN promotes neutrophil migration via ERK and
p38 MAP kinase activation.
Abbreviations
Ab: antibody; ALI: acute lung injury; ALT: alanine aminotransferase;
ARDS: acute respiratory distress syndrome; AST: aspartate aminotransferase;
BSP-I: bone sialoprotein-I; CLP: cecal ligation and puncture; DC: dendritic
cells; DMSO: dimethyl sulfoxide; ELISA: enzyme-linked immunosorbent assay;
ERK: extracellular signal-regulated protein kinase; ETA-1: early T lymphocyte
activation; FAK: focal adhesion kinase; FBS: fetal bovine serum; GRK: G
protein-coupled receptor kinase; H&E: hematoxylin and eosin; ICU: intensive
care unit; IgG: immunoglobulin G; IL: interleukin; JNK: Jun N-terminal kinase;
kDa: kiloDalton; LDH: lactate dehydrogenase; MAP: mitogen-activated protein;
MIP: macrophage inflammatory protein; MMP: matrix metalloproteinase;
MOF: multiple organ dysfunction; MPO: myeloperoxidase; NK: natural killer;
OD: optical density; OPN: osteopontin; PBS: phosphate-buffered saline;
PCR: polymerase chain reaction; PI: propidium iodide; rmOPN: recombinant
mouse OPN; ROS: reactive oxygen species; SAPK: stress-activated protein kinase;
SEM: standard error of the mean; SPP-1: secreted phosphoprotein-1; TBST:
Tris-buffered saline with Tween-20; Th1: T helper type 1.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
YH and MA designed and performed the experiments. YH and MA analyzed
the data and prepared the manuscript. W-LY analyzed the data and helped in
manuscript preparations. ZW performed in vivo experiments. MZ supervised
and carried out immunohistochemical work. MO did the animal work. AK
helped in performing the statistical analysis. PW conceived the idea, reviewed
the manuscript and supervised the whole project. All authors read and
approved the final manuscript.
Acknowledgements
This study was supported by the National Institutes of Health (NIH) grants
GM053008 and GM057468 (P.W.).
Author details
1Department of Surgery, Hofstra North Shore-LIJ School of Medicine and
Center for Translational Research, The Feinstein Institute for Medical Research,
350 Community Drive, Manhasset, NY 11030, USA. 2Department of
Emergency and Critical Care Medicine, Juntendo University, Urayasu Hospital,
2-1-1 Tomioka, Urayasu, Chiba 279-0021, Japan.
Received: 31 October 2014 Accepted: 2 February 2015
References
1. Aziz M, Jacob A, Yang WL, Matsuda A, Wang P. Current trends in
inflammatory and immunomodulatory mediators in sepsis. J Leukoc Biol.
2013;93:329–42.
2. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The
natural history of the systemic inflammatory response syndrome (SIRS):
a prospective study. JAMA. 1995;273:117–23.
3. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR.
Epidemiology of severe sepsis in the United States: analysis of incidence,
outcome, and associated costs of care. Crit Care Med. 2001;29:1303–10.
4. Matuschak GM, Lechner AJ. Acute lung injury and the acute respiratory
distress syndrome: pathophysiology and treatment. Mo Med. 2010;107:252–8.
5. Rubenfeld GD, Caldwell E, Peabody E, Weaver J, Martin DP, Neff M, et al.
Incidence and outcomes of acute lung injury. N Engl J Med. 2005;353:1685–93.
6. Aziz M, Matsuda A, Yang WL, Jacob A, Wang P. Milk fat globule-epidermal
growth factor-factor 8 attenuates neutrophil infiltration in acute lung injury
via modulation of CXCR2. J Immunol. 2012;189:393–402.7. Giangola MD, Yang WL, Rajayer SR, Nicastro J, Coppa GF, Wang P. Growth
arrest-specific protein 6 attenuates neutrophil migration and acute lung
injury in sepsis. Shock. 2013;40:485–91.
8. Abraham E. Neutrophils and acute lung injury. Crit Care Med. 2003;31:S195–9.
9. Lee WL, Downey GP. Neutrophil activation and acute lung injury. Curr Opin
Crit Care. 2001;7:1–7.
10. Windsor ACJ. Role of the neutrophil in adult respiratory distress syndrome.
Br J Surg. 1993;80:10–7.
11. Lund SA, Giachelli CM, Scatena M. The role of osteopontin in inflammatory
processes. J Cell Commun Signal. 2009;3:311–22.
12. Agnholt J, Kelsen J, Schack L, Hvas CL, Dahlerup JF, Sorensen ES.
Osteopontin, a protein with cytokine-like properties, is associated with
inflammation in Crohn’s disease. Scand J Immunol. 2007;65:453–60.
13. El-Tanani MK, Campbell FC, Kurisetty V, Jin D, McCann M, Rudland PS. The
regulation and role of osteopontin in malignant transformation and cancer.
Cytokine Growth Factor Rev. 2006;17:463–74.
14. Golledge J, Muller J, Shephard N, Clancy P, Smallwood L, Moran C, et al.
Association between osteopontin and human abdominal aortic aneurysm.
Arterioscler Thromb Vasc Biol. 2007;27:655–60.
15. Kariuki SN, Moore JG, Kirou KA, Crow MK, Utset TO, Niewold TB. Age- and
gender-specific modulation of serum osteopontin and interferon-alpha by
osteopontin genotype in systemic lupus erythematosus. Genes Immun.
2009;10:487–94.
16. Comabella M, Pericot I, Goertsches R, Nos C, Castillo M, Blas Navarro J, et al.
Plasma osteopontin levels in multiple sclerosis. J Neuroimmunol.
2005;158:231–9.
17. Sennels H, Sorensen S, Ostergaard M, Knudsen L, Hansen M, Skjodt H, et al.
Circulating levels of osteopontin, osteoprotegerin, total soluble receptor
activator of nuclear factor-kappa B ligand, and high-sensitivity C-reactive
protein in patients with active rheumatoid arthritis randomized to etanercept
alone or in combination with methotrexate. Scand J Rheumatol.
2008;37:241–7.
18. Wang KX, Denhardt DT. Osteopontin, role in immune regulation and stress
responses. Cytokine Growth Factor Rev. 2008;19:333–45.
19. Cantor H, Shinohara ML. Regulation of T-helper-cell lineage development by
osteopontin, the inside story. Nat Rev Immunol. 2009;9:137–41.
20. Santamaria MH, Corral RS. Osteopontin-dependent regulation of Th1 and
Th17 cytokine responses in Trypanosoma cruzi-infected C57BL/6 mice.
Cytokine. 2013;61:491–8.
21. Goncalves DaSilva A, Liaw L, Yong VW. Cleavage of osteopontin by matrix
metalloproteinase-12 modulates experimental autoimmune encephalomyelitis
disease in C57BL/6 mice. Am J Pathol. 2010;177:1448–58.
22. Agnihotri R, Crawford HC, Haro H, Matrisian LM, Havrda MC, Liaw L.
Osteopontin, a novel substrate for matrix metalloproteinase-3 (stromelysin-1)
and matrix metalloproteinase-7 (matrilysin). J Biol Chem. 2001;276:28261–7.
23. Weber GF, Zawaideh S, Hikita S, Kumar VA, Cantor H, Ashkar S.
Phosphorylation-dependent interaction of osteopontin with its receptors
regulates macrophage migration and activation. J Leukoc Biol. 2002;72:752–61.
24. Van der Windt GJW, Hoogendijk AJ, Schouten M, Hommes TJ, de Vos AF,
Florquin S, et al. Osteopontin impairs host defense during pneumococcal
pneumonia. J Infect Dis. 2011;203:1850–8.
25. Van der Windt GJW, Wiersinga WJ, Wieland CW, Tjia IC, Day NP, Peacock SJ, et al.
Osteopontin impairs host defense during established Gram-negative sepsis
caused by Burkholderia pseudomallei (Melioidosis). PLoS Negl Trop Dis.
2010;4:e806.
26. Van der Windt GJW, Hoogerwerf JJ, de Vos AF, Florquin S, van der POLL T.
Osteopontin promotes host defense during Klebsiella pneumonia-induced
pneumonia. Eur Respir J. 2010;36:1337–45.
27. Vaschetto R, Nicola S, Olivieri C, Boggio E, Piccolella F, Mesturini R, et al.
Serum levels of osteopontin are increased in SIRS and sepsis. Intensive Care
Med. 2008;34:2176–84.
28. O’Regan AW, Chupp GL, Lowry JA, Goetschkes M, Mulligan N, Berman JS.
Osteopontin is associated with T cells in sarcoid granulomas and has T cell
adhesive and cytokine-like properties in vitro. J Immunol. 1999;162:1024–31.
29. Koh A, Silva APB, Bansal AK, Bansal M, Sun C, Lee H, et al. Role of
osteopontin in neutrophil function. Immunology. 2007;122:466–75.
30. Xanthou G, Alissafi T, Semitekolou M, Simoes DC, Economidou E, Gaga M,
et al. Osteopontin has a crucial role in allergic airway disease through
regulation of dendritic cell subsets. Nat Med. 2007;13:570–8.
31. Murugaiyan G, Mittal A, Weiner HL. Increased osteopontin expression in
dendritic cells amplifies IL-17 production by CD4+ T cells in experimental
Hirano et al. Critical Care  (2015) 19:53 Page 15 of 15autoimmune encephalomyelitis and in multiple sclerosis. J Immunol.
2008;181:7480–8.
32. Bachofen M, Weibel ER. Structural alterations of lung parenchyma in the
adult respiratory distress syndrome. Clin Chest Med. 1982;3:35–56.
33. Hickey MJ. Has Ly6G finally found a job? Blood. 2012;120:1352–3.
34. Huang C, Jacobson K, Schaller MD. MAP kinases and cell migration. J Cell
Sci. 2004;117:4619–28.
35. Lehman JA, Paul CC, Baumann MA, Gomez-Cambronero J. MAP kinase
upregulation after hematopoietic differentiation: role of chemotaxis. Am J
Physiol Cell Physiol. 2001;280:C183–91.
36. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M,
Zawaideh S, et al. Eta-1(osteopontin); an early component of type-1
(cell mediated) immunity. Science. 2000;287:860–4.
37. Nystrom T, Duner P, Hultgardh-Nilsson A. A constitutive endogenous
osteopontin production is important for macrophage function and
differentiation. Exp Cell Res. 2007;313:1149–60.
38. Scatena M, Liaw L, Giachelli CM. Osteopontin: a multifunctional molecule
regulating chronic inflammation and vascular disease. Arterioscler Thromb
Vasc Biol. 2007;27:2302–9.
39. Lane D, Matte I, Laplante C, Garde-Granger P, Rancourt C, Piché A.
Osteoprotegerin (OPG) activates integrin, focal adhesion kinase (FAK),
and Akt signaling in ovarian cancer cells to attenuate TRAIL-induced
apoptosis. J Ovarian Res. 2013;6:82.
40. Hu B, Jarzynka MJ, Guo P, Imanishi Y, Schlaepfer DD, Cheng SY.
Angiopoietin 2 induces glioma cell invasion by stimulating matrix
metalloprotease 2 expression through the alphavbeta1 integrin and focal
adhesion kinase signaling pathway. Cancer Res. 2006;66:775–83.
41. Lu M, Munger JS, Steadele M, Busald C, Tellier M, Schnapp LM. Integrin
alpha8beta1 mediates adhesion to LAP-TGFbeta1. J Cell Sci. 2002;115:4641–8.
42. Liaw L, Birk DE, Ballas CB, Whitsitt JS, Davidson JM, Hogan BL. Altered
wound healing in mice lacking a functional osteopontin gene (spp 1). J Clin
Invest. 1998;101:1468–78.
43. O’Brien ER, Garvin MR, Stewart DK, Hinohara T, Simpson JB, Schwartz SM,
et al. Osteopontin is synthesized by macrophage, smooth muscle, and
endothelial cells in primary and restenotic human coronary atherosclerotic
plaques. Arterioscler Thromb. 1994;14:1648–56.
44. Vaschetto R, Navalesi P, Clemente N, Boggio E, Valsecchi S, Olivieri C, et al.
Osteopontin induces soluble urokinase-type plasminogen activator receptor
production and release. Minerva Anestesiol. 2015;81:157–65.
45. Warren HS. Editorial: Mouse models to study sepsis syndrome in humans.
J Leukoc Biol. 2009;86:199–201.
46. Bruemmer D, Collins AR, Noh G, Wang W, Territo M, Arias-Magallona S, et al.
Angiotensin 2-accelerated atherosclerosis and aneurysm formation is attenuated
in osteopontin-deficient mice. J Clin Invest. 2003;112:1318–31.
47. Atai NA, Bansal M, Lo C, Man J, Tigchelaar W, Bosch KS, et al. Osteopontin is
up-regulated and associated with neutrophil and macrophage infiltration in
glioblastoma. Immunology. 2011;132:39–48.
48. Kiefer FW, Zeyda M, Gollinger K, Pfau B, Neuhofer A, Weichhart T, et al.
Neutralization of osteopontin inhibits obesity-induced inflammation and
insulin resistance. Diabetes. 2010;59:935–46.
49. Fortis S, Khadaroo RG, Haitsma JJ, Zhang H. Osteopontin is associated with
inflammation and mortality in a mouse model of polymicrobial sepsis. Acta
Anaesthesiol Scand. 2015;59:170–5.
50. Liu X, Ma B, Malik AB, Tang H, Yang T, Sun B, et al. Bidirectional regulation
of neutrophil migration by mitogen-activated protein kinases. Nat Immunol.
2012;13:457–64.
51. Kim D, Haynes CL. The role of p38 MAPK in neutrophil functions: single cell
chemotaxis and surface marker expression. Analyst. 2013;138:6826–33.
52. Bogoyevitch MA, Ngoei KR, Zhao TT, Yeap YY, Ng DC. c-Jun N-terminal
kinase (JNK) signaling: recent advances and challenges. Biochim Biophys
Acta. 2010; 1804:463–75.
53. Zhao X, Guan JL. Focal adhesion kinase and its signaling pathways in cell
migration and angiogenesis. Adv Drug Deliv Rev. 2011;63:610–5.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
